Introduction
Dr. Ahmed Refae, Dr. Omalkhair Abulkhair, Dr. Meteb Al-Foheidi, Dr. Abdullah Altwairgi, and Dr. Esam Murshid discuss the implications of the Overall Survival (OS) data of CDK 4 & 6 Inhibitors on patients management in clinical practice.
Objectives
To discuss and share:
1. The Overall Survival data of CDK 4 & 6 inhibitors
2. HR+ HER2- MBC patients with less favorable prognosis management
3. CDK 4 & 6 inhibitors adverse event management
This Course For :
Physician
Resident / Fellow
Pharmacy
Sponsored by :
Price
Course Fee
FREE
FREE
Contact Information
Organization : Virtual Medical AcademyPhone : 920008161
Email : [email protected]
Free
18 May 2020 To 18 May 2020 -
08:30 PM To 10:00 PM 
Certificate Available 
SCFHS 2 CME hours
Online Click Here
- 2217
Add to Calendar
05/18/2020 08:30 PM
05/18/2020 10:00 PM
Asia/ Riyadh
Expert Panel Discussion on Metastatic Breast Cancer (MBC)
Expert Panel Discussion on Metastatic Breast Cancer (MBC)
https://medicalacademy.org/portal/event/view/1137
